Drugs / 18F-FSPG
18F-FSPG
Trials 12 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05322135 | Sep 2022 → Mar 2025 | head and neck squamous cell carcinoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 15 trials | ||||||
| Phase 1 | NCT02379377 | Feb 2022 → May 2027 expected | adult hepatocellular carcinoma, cholangiocarcinoma, hepatobiliary benign neoplasm | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03275974 | Apr 2021 → Dec 2025 | colorectal cancer | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT02370563 | Nov 2014 → Mar 2016 | brain cancer | Lantheus Biosciences Ltd. | Terminated | No outcome recorded |
| Phase 1 | NCT01186601 | Dec 2010 → Oct 2011 | neoplasm | Lantheus Biosciences Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01103310 | Apr 2010 → Aug 2011 | neoplasm | Lantheus Biosciences Ltd. | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT04488094 | Nov 2020 → Mar 2023 | transplant rejection | Asan Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT03824535 | Feb 2019 → Jul 2021 | pulmonary coin lesion | Andrei Iagaru | Completed | No outcome recorded |
| Phase 2 | NCT03546868 | Aug 2018 → Jan 2019 | Crohn disease, ulcerative colitis | Asan Foundation | Completed | No outcome recorded |
| Phase 2 | NCT03103490 | Aug 2017 → Sep 2021 | cardiac sarcoidosis, myocarditis | Stanford University | Terminated | No outcome recorded |
| Phase 2 | NCT02599194 | Jul 2015 → Dec 2016 | B-cell neoplasm, malignant mesothelioma, non-small cell lung carcinoma, renal cell carcinoma +1 | Andrei Iagaru | Completed | No outcome recorded |
| Phase 2 | NCT02448225 | Jun 2015 → Aug 2021 | lung carcinoma, pulmonary coin lesion | Vanderbilt-Ingram Cancer Center | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-FSPG | “To establish and validate a 11C-glutamine (11C-Gln) and fluorine F 18 L-glutamate derivative BAY94-9392 (18F-FSPG) PET image guided gene signature to predict response to...” NCT03275974 ↗ |
| Known as | (4S)-4-(3-[18F]fluoropropyl)-l-glutamate | “The PET tracer (4S)-4-(3-[18F]fluoropropyl)-l-glutamate (18F-FSPG) targets the system xC- cotransporter, which is overexpressed in various tumors.” PMID 35191738 ↗ Feb 2022 |
| Known as | (f18) florilglutamic acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL5316159 ↗ |
| Known as | BAY94-9392 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01186601 ↗ |
| Known as | Florilglutamic acid ((sup 18)f) | ChEMBL registry synonym — accepted as the source's own label CHEMBL5316159 ↗ |
| Known as | Florilglutamic acid (18-f) | ChEMBL registry synonym — accepted as the source's own label CHEMBL5316159 ↗ |
| Known as | FLORILGLUTAMIC ACID F-18 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5316159 ↗ |
| Known as | Fluorine F 18 L-glutamate Derivative BAY94-9392 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03824535 ↗ |
| Known as | Fspg f-18 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5316159 ↗ |
| Modality | Diagnostic / imaging agent | “the 18F-labeled PET/CT (Positron Emission Tomography / Computed Tomography) Tracer BAY94-9392” NCT01103310 ↗ |
| Route | Intravenous | “single intravenous bolus injection of 300 MBq BAY94-9392” NCT01103310 ↗ |